Log In
Print
BCIQ
Print
Print this Print this
 

IV rolapitant (SCH 619734)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionNeurokinin 1 (NK1) substance P receptor (TACR1) antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1)
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentRegistration
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation
Partner Tesaro Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$6.0M

$115.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today